Oral Bropirimine Immunotherapy of
Rodent Prostate Cancer

Sarosdy, Michael F.

doi:10.1159/000474525

Cited by 6 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study showed that it is easier to achieve delayed tumour growth with vaccines in the Lobund–Wistar rat model, a finding reported by others using the nonspecific biological response modifier, bropirimine [21]. This may be because the PAIII tumour is a better target for immunity than MAT‐Ly‐Lu, possibly because it has higher levels of MHC.…”

Section: Discussionsupporting

confidence: 80%

Allogeneic whole‐tumour cell vaccination in the rat model of prostate cancer

Hrouda

Todryk²,

Perry

et al. 2000

BJU International

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 80%

Allogeneic whole‐tumour cell vaccination in the rat model of prostate cancer

Hrouda

Todryk²,

Perry

et al. 2000

BJU International

View full text Add to dashboard Cite

“…Bropirimine is described as antiviral and antineoplastic agent [88]. It was tested as agent against melanoma [89], bladder tumor [90e92], prostate cancer [93] and renal cell carcinoma [94].…”

Section: Pyrimidine and Purine Base Derivativesmentioning

confidence: 99%

Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes

Patinote

Karroum

Moarbess

et al. 2020

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

a b s t r a c tThe discovery of the TLRs family and more precisely its functions opened a variety of gates to modulate immunological host responses. TLRs 7/8 are located in the endosomal compartment and activate a specific signaling pathway in a MyD88-dependant manner. According to their involvement into various autoimmune, inflammatory and malignant diseases, researchers have designed diverse TLRs 7/8 ligands able to boost or block the inherent signal transduction. These modulators are often small synthetic compounds and most act as agonists and to a much lesser extent as antagonists. Some of them have reached preclinical and clinical trials, and only one has been approved by the FDA and EMA, imiquimod. The key to the success of these modulators probably lies in their combination with other therapies as recently demonstrated. We gather in this review more than 360 scientific publications, reviews and patents, relating the extensive work carried out by researchers on the design of TLRs 7/8 modulators, which are classified firstly by their biological activities (agonist or antagonist) and then by their chemical structures, which total syntheses are not discussed here. This review also reports about 90 clinical cases, thereby showing the biological interest of these modulators in multiple pathologies.

show abstract

“…Antagonists of bombesin/gastrin‐releasing peptide combined with agonists of LHRH exert strong inhibitory activity against the Dunning R‐33237H cancer 577. Treatment of cancer‐bearing rats with an aryl pyrimidone, bropirimine, and prostatectomy decreased residual cancer, decreased the expression of proliferating cell nuclear antigen (PCNA) and TGF‐β‐1, and prolonged survival 578. Bropirimine may play a role in the treatment of human prostate cancer as adjuvant therapy in combination with prostatectomy 579…”

Section: 0 Goalsmentioning

confidence: 99%